Drug Profile
BMS 394136
Alternative Names: BMS-394136Latest Information Update: 16 Sep 2014
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antiarrhythmics; Heterocyclic bicyclo compounds; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Kv1.5 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 16 Sep 2014 Discontinued - Phase-I for Arrhythmias in USA (PO)